Bitcoin's price dropped below $80,000 following the release of US Producer Price Index (PPI) data showing the largest increase in four years. This rise in PPI suggests higher inflation pressures, which can influence investor sentiment and market volatility. The dip in Bitcoin reflects concerns that inflation could lead to tighter monetary policies. Investors will be watching upcoming economic data and central bank moves closely for further direction.
Capital B's reported $78M H1 loss provides context for cryptocurrency market conditions. For readers following crypto assets, here is Pluang's market snapshot as of Oct 16, 2026 14:21 WIB: out of 50 major cryptocurrencies, 47 rose and 2 fell today. Notable movers include XTZ (Tezos) up 8.09% with 77% sell order activity, ALGO (Algorand) up 7.95% with 68% buy order activity, and ZIL (Zilliqa) up 7.94% with 100% buy order activity and typical hold time of 133 days.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
